journal article·2026-11Open access

Engineered protein nanoclusters reduce liver fibrosis and hepatocellular carcinoma in mice models

Tanya Saxena, Gabriela Guedes, Inês Domingues, Hafsa Yagoubi, Léo Guilbaud, William Van den Bossche, Cristina Pangua, Greetje Vande Velde, Bernard Ucakar, Andrea García-Esnaola, Isabelle Leclercq, Aitziber L. Cortajarena, Ana Beloqui

Abstract

Long-term liver injury leads to acute hepatitis and chronic liver diseases, including fibrosis and hepatocellular carcinoma (HCC), which frequently necessitate liver transplantation and are associated with poor median survival. Transforming growth factor-β (TGF-β) signalling pathway is a key driver of fibrogenesis and tumor progression. Therapeutic approaches targeting this pathway-via TGF-β receptor blockade or inhibition of its chaperone protein Hsp90- are under pre-clinical and clinical trials, and despite some promising results none of them has been adopted as a definitive therapy. Engineered protein scaffolds have emerged as an attractive alternative owing to their high engineerability and ease of production. In particular, consensus tetratricopeptide repeat (CTPR) proteins are strong candidates because of their modularity, robustness, design flexibility, and amenability to functionalization. Here, we investigate the protein-nanocluster hybrid formulation comprising C390 and nanocluster-stabilizing domain (C390-AuNC) as a Hsp90 inhibitory platform to assess its potential dual anti-fibrotic and anti-tumor activity in two chemically-induced murine liver disease models: acute liver fibrosis and chronic HCC. In the fibrosis model, C390-AuNC markedly suppress the expression of profibrotic markers and promote degradation of collagen fibers in the liver, indicating effective attenuation of fibrogenesis. In the HCC model, C390-AuNC inhibit Hsp90, leading to reduced expression of oncogenic proteins that drive cancer cell proliferation and metastasis, and consequently diminish tumor burden. Collectively, these findings support C390-AuNC as a promising next-generation biotherapeutic platform with low anticipated immunogenicity and high therapeutic potential.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Heat shock proteins research · Peptidase Inhibition and Analysis · Hepatitis B Virus Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (53)

Show source-provided references
1. The evidence-based multifaceted roles of hepatic stellate cells in liver diseases: a concise review10.1016/j.lfs.2024.122547 ↗
2. Global prevalence of advanced liver fibrosis and cirrhosis in the general population: a systematic review and meta-analysis10.1016/j.cgh.2024.08.020 ↗
3. Global burden of liver disease: 2023 update10.1016/j.jhep.2023.03.017 ↗
4. Hepatocellular carcinoma: signaling pathways and therapeutic advances10.1038/s41392-024-02075-w ↗
5. Hepatocellular carcinoma-the role of the underlying liver disease in clinical practice10.3748/wjg.v30.i19.2488 ↗
6. Liver transplantation for hepatocellular carcinoma: where do we stand?10.3748/wjg.v25.i21.2591 ↗
7. Decoding the roles of heat shock proteins in liver cancer10.1016/j.cytogfr.2023.12.003 ↗
8. Hepatocellular carcinoma: mouse models and the potential roles of proteases10.1016/j.canlet.2016.03.047 ↗
9. The TGF-Beta signaling pathway as a pharmacological target in a hepatocellular carcinoma10.2174/138161212802430431 ↗
10. The TGF-Beta pathway: a pharmacological target in hepatocellular carcinoma?10.3390/cancers13133248 ↗
11. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma10.1111/liv.14113 ↗
12. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-beta monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors10.1136/jitc-2023-007353 ↗
13. First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ss1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors10.3389/fonc.2024.1376551 ↗
14. The safety and side effects of monoclonal antibodies10.1038/nrd3003 ↗
15. Reproducibility: standardize antibodies used in research10.1038/518027a ↗
16. The role of heat shock proteins in the regulation of fibrotic diseases10.1016/j.biopha.2020.111067 ↗
17. Reduction of cardiac TGFbeta-mediated profibrotic events by inhibition of Hsp90 with engineered protein10.1016/j.yjmcc.2018.08.016 ↗
18. The HSP90 family: structure, regulation, function, and implications in health and disease10.3390/ijms19092560 ↗
19. Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors10.2217/fon-2022-1172 ↗
20. Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs10.1016/j.freeradbiomed.2010.03.001 ↗
21. New insights into protein-protein interaction modulators in drug discovery and therapeutic advance10.1038/s41392-024-02036-3 ↗
22. DARPins and other repeat protein scaffolds: advances in engineering and applications10.1016/j.copbio.2011.06.004 ↗
23. Design of stable alpha-helical arrays from an idealized TPR motif10.1016/S0969-2126(03)00076-5 ↗
24. Protein design to understand peptide ligand recognition by tetratricopeptide repeat proteins10.1093/protein/gzh047 ↗
25. Designed TPR modules as novel anticancer agents10.1021/cb700260z ↗
26. Engineering multifunctional metal/protein hybrid nanomaterials as tools for therapeutic intervention and high-sensitivity detection10.1039/D0SC05215A ↗
27. Correlative 3D cryo X-ray imaging reveals intracellular location and effect of designed antifibrotic protein-nanomaterial hybrids10.1039/D1SC04183E ↗
28. Fibroblast-derived extracellular vesicles as trackable efficient transporters of an experimental nanodrug with fibrotic heart and lung targeting10.7150/thno.85409 ↗
29. White-Emitting gold nanocluster assembly with dynamic color tuning10.1021/acs.nanolett.4c01377 ↗
30. Red-emitting Au7 nanoclusters with fluorescence sensitivity to Fe2+ ions10.1039/C7TC00724H ↗
31. Structure and stability of designed TPR protein superhelices: unusual crystal packing and implications for natural TPR proteins10.1107/S0907444907024353 ↗
32. A simple approach to design proteins for the sustainable synthesis of metal nanoclusters10.1002/anie.201813576 ↗
33. In vivo and in vitro models to Study liver fibrosis: mechanisms and limitations10.1016/j.jcmgh.2023.05.010 ↗
34. Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells10.1038/s41423-025-01313-7 ↗
35. Inducible knockdown of procollagen I protects mice from liver fibrosis and leads to dysregulated matrix genes and attenuated inflammation10.1016/j.matbio.2017.11.002 ↗
36. Inhibition of fibronectin deposition improves experimental liver fibrosis10.1016/j.jhep.2014.06.010 ↗
37. Fibrosis and hepatocarcinogenesis: role of gene-environment interactions in liver disease progression10.3390/ijms25168641 ↗
38. Automated thermal imaging for the detection of fatty liver disease10.1038/s41598-020-72433-5 ↗
39. Histopathological evaluation of liver fibrosis and cirrhosis regression10.3350/cmh.2017.0078 ↗
40. Animal models for fibrotic liver diseases: what we have, what we need, and what is under development10.14218/JCTH.2014.00035 ↗
41. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan10.1038/s41467-019-10968-6 ↗
42. Glomerular barrier behaves as an atomically precise bandpass filter in a sub-nanometre regime10.1038/nnano.2017.170 ↗
43. In vivo renal clearance, biodistribution, toxicity of gold nanoclusters10.1016/j.biomaterials.2012.03.020 ↗
44. Luminescent gold nanoparticles with efficient renal clearance10.1002/anie.201007321 ↗
45. Downregulation of A20 increases the cytotoxicity of IFN-gamma in hepatocellular carcinoma cells10.2147/DDDT.S135993 ↗
46. Moulder · 1995
47. QuPath: open source software for digital pathology image analysis10.1038/s41598-017-17204-5 ↗
48. Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease10.1007/s13346-024-01576-z ↗
49. Enterohepatic takeda G-Protein coupled receptor 5 agonism in metabolic dysfunction-associated fatty liver disease and related glucose dysmetabolism10.3390/nu14132707 ↗
50. The endogenous bioactive lipid prostaglandin D(2)-glycerol ester reduces murine colitis via DP1 and PPARgamma receptors10.1096/fj.201701205R ↗
51. Use of infrared thermal imaging for assessing acute inflammatory changes: a case series
52. Assessment of pain and inflammation in domestic animals using infrared thermography: a narrative review
53. The role of TGF-beta/SMAD signaling in hepatocellular carcinoma: from mechanism to therapy and prognosis10.7150/ijbs.89568 ↗